Health Canada
EVENT
Advisory Committee: Implementation Advisory Group (IAG) for the National Strategy for Drugs for Rare Diseases
Published: 10/2/2026Detected: 3/19/2026
Summary preview
Establishes an Implementation Advisory Group (IAG) to support execution of Canada’s National Strategy for Drugs for Rare Diseases, providing a structured forum to advise Health Canada on how rare-disease drug…
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountrare_diseases
clinical
safety
quality
labeling
manufacturing
#rare diseases
#advisory committee
#implementation advisory group
#Health Canada
#drug strategy
Official Source Document Source Verified
Access the original document directly from HEALTH CANADA.
More from Health Canada
- Advisory Committee: Review of the Federal Approach to Pandemic Science Advice and Research Coordination10/2/2026
- Advisory Committee: National Pharmacare Committee of Experts10/2/2026
- Advisory Committee: Ministerial Advisory Council on Mental Health10/2/2026
- Advisory Committee: Expert Task Force on Substance Use10/2/2026
- Advisory Committee: Expert Panel on MAID and Mental Illness10/2/2026